EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma

Takayoshi Hattori iD, Makiko Fujii, Tsutomu Ueda iD, Akira Ishikawa iD, Yuichi Mine iD, Bingwen Xu, Tomoya Suehiro, Minoru Hattori iD, Hiroaki Tahara, Yuki Sato, Nobuyuki Chikuie, Takayuki Taruya and 3 more

Otolaryngology–Head and Neck Surgery · 2026

DOI: 10.1002/ohn.70137 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2026. Written by Takayoshi Hattori and 14 co-authors. Institution: Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Major MEDLINE topics: Cyclin-Dependent Kinase 4, Melanoma, Head and Neck Neoplasms, Piperazines. 40 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Objective

Mucosal melanoma (MM) is an extremely aggressive malignant tumor in the head and neck region associated with a poor prognosis. In the present study, we conducted cell proliferation assay and western blotting using cell lines derived from MM and the immunohistochemical analysis of pathological MM tissues to identify novel therapeutic targets. Herein, we report on the potential of cyclin‐dependent kinase 4 (CDK4) inhibitors as molecular targeted therapies for MM. Study Design Retrospective cohort study and laboratory analysis.

Setting

A tertiary referral center.

Methods

MTT assay and western blotting were performed on the HMV‐II (RCB0777) and GAK (JCRB0180) cell lines, treated with the CDK4 inhibitors abemaciclib (LY2835219) and palbociclib (PD‐0332991). This retrospective cohort study included patients with head and neck MM; immunohistochemistry was performed on clinical specimens.

Results

Abemaciclib and palbociclib showed concentration‐dependent cytostatic effects on HMV‐II and GAK cells at 72 hours in the MTT assay. In western blotting, they exhibited concentration‐dependent inhibitory effects on phosphorylated RB1 in HMV‐II and GAK cells at 24 hours. Of 23 patients, 18 (78.3%) had positive results on CDK4 immunostaining. No clinicopathologic factors were significantly associated with CDK4 status.

Conclusion

Abemaciclib and palbociclib may suppress MM cell proliferation. The CDK4 signaling pathway is a potential target for molecular‐targeted therapies in MM.

Subjects

MeSH terms (MEDLINE)

Cyclin-Dependent Kinase 4MelanomaHead and Neck NeoplasmsPiperazinesAminopyridinesBenzimidazolesPyridinesHumansRetrospective StudiesFemaleMaleCell ProliferationCell Line, TumorMucous MembraneMiddle AgedImmunohistochemistryAgedBlotting, WesternMolecular Targeted Therapy

Author keywords

cell linecyclin‐dependent kinase 4growth inhibitorshead and neckmolecular‐targeted therapymucosal melanoma

Substances

Cyclin-Dependent Kinase 4PiperazinesAminopyridinesBenzimidazolesPyridinesabemaciclibpalbociclibCDK4 protein, human

Authors and institutions

  • Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Genomic Oncology, Oral Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Medical Systems Engineering, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Medical Education Institute of Biomedical & Health Sciences, Center for Medical Education Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.

ORCID profiles: Takayoshi Hattori, Tsutomu Ueda, Akira Ishikawa, Yuichi Mine, Minoru Hattori, Takashi Ishino, Sachio Takeno

Cite

APA

Hattori, T., Fujii, M., Ueda, T., Ishikawa, A., Mine, Y., Xu, B., Suehiro, T., Hattori, M., Tahara, H., Sato, Y., Chikuie, N., Taruya, T., Hamamoto, T., Ishino, T., & Takeno, S. (2026). Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70137

Vancouver

Hattori T, Fujii M, Ueda T, Ishikawa A, Mine Y, Xu B, et al. Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70137

BibTeX
@article{Hattori2026,
  author = {Hattori, Takayoshi and Fujii, Makiko and Ueda, Tsutomu and Ishikawa, Akira and Mine, Yuichi and Xu, Bingwen and Suehiro, Tomoya and Hattori, Minoru and Tahara, Hiroaki and Sato, Yuki and Chikuie, Nobuyuki and Taruya, Takayuki and Hamamoto, Takao and Ishino, Takashi and Takeno, Sachio},
  title = {Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2026},
  doi = {10.1002/ohn.70137}
}
Start for free →